@misc{indiciae90f8be43e838,
  title = {T-cell targeted immunotherapy against the tumor associated antigen survivin (BIRC5) as a potential neoadjuvant immunotherapy for triple negative breast cancer.},
  author = {Burkholz, S. R. and Herst, C. V. and Carback, R. T. and Harris, P. E. and Rubsamen, R. M.},
  year = {2022},
  doi = {10.1101/2022.07.25.501455},
  url = {https://www.biorxiv.org/content/10.1101/2022.07.25.501455v1},
  note = {Source identifier: 10.1101/2022.07.25.501455}
}